An ADME Study of [14C]AZD0780 in Healthy Male Subjects
Status:
Not yet recruiting
Trial end date:
2023-05-24
Target enrollment:
Participant gender:
Summary
The Sponsor is developing a new test medicine, AZD0780, with the aim to lower low-density
lipoprotein cholesterol (LDL-C, fatty deposits) levels and cardiovascular (heart disease)
risk, when given on top of standard care.
This two-part healthy volunteer study will try to identify how the test medicine is taken up,
broken down and removed from the body. To help investigate this, the test medicine is
radiolabelled, which means that the test medicine has a radioactive component (carbon-14;
also referred as 14C) which helps us to track where the test medicine is in the body. The
safety and tolerability of the test medicine will also be studied.
This study will take place at one non-NHS site, enrolling up to 8 male volunteers aged
between 30 and 55 years.